德适生物(2526.HK)与蚂蚁/杭钢背景的浙江安诊儿订立三年医学影像AI合作框架协议

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility
for the contents of this announcement, make no representation as to its accuracy or completeness and expressly
disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the
contents of this announcement.

Hangzhou Diagens Biotechnology Co., Ltd.
杭州德適生物科技股份有限公司

(A joint stock company incorporated in the People ’s Republic of China with limited liability)

(Stock Code: 2526)

VOLUNTARY ANNOUNCEMENT
ENTERING INTO THE COOPERATION FRAMEWORK AGREEMENT
WITH ZHEJIANG ANZHEN’ER MEDICAL ARTIFICIAL INTELLIGENCE
TECHNOLOGY CO., LTD.
This announcement is made by Hangzhou Diagens Biotechnology Co., Ltd. (the “Company”,
together with its subsidiaries, the “Group”) on a voluntary basis to inform the shareholders and
potential investors of the Company about the latest business update.
The board of directors of the Company (the “Board”) is pleased to announce that the Company
has entered into a cooperation framework agreement with Zhejiang Anzhen’er Medical Artificial
Intelligence Technology Co., Ltd. (浙江省安診兒醫學人工智能科技有限公司) (“Anzhen’er”) to
carry out cooperation centering on medical imaging artificial intelligence, primary-level imaging
cloud services and medical data products, with a cooperation term of three years from the date of
signing.
Both parties intend to combine the multimodal medical imaging capabilities of the Group’ s
iMedImage® with Anzhen’er’s unique resources, with focus on pre-diagnosis consultations, initial
imaging screening and report interpretation, to jointly build a provincial-level capability base
for “digital and intelligent imaging ” and establish a provincial benchmark for the application
of medical large models; leverage the pilot test base operations and medical institution synergy
resources of Anzhen’er to explore an imaging cloud service model of “examination at the primary
level, identification in the cloud, and review at the provincial level”, jointly building the Zhejiang
provincial medical imaging AI-assisted diagnosis cloud platform; and jointly develop high-quality
medical datasets, artificial intelligence training corpora, as well as scientific research and data
analysis products, while exploring new models for the capitalization of medical data.

1

The Board believes that this cooperation will help combine the Group ’ s medical imaging
foundation model and software and hardware product capabilities with the medical resource
coordination, clinical scenario organization, and achievement transformation support of the
national pilot base, drive collaborative innovation among medical institutions, scientific research
institutions, and enterprises around clinical needs through specific projects, explore the research
and development, validation, and application of high-quality datasets, disease-specific models,
and innovative products, and expand the upper limit of medical scientific research and diagnostic
and treatment innovation. The Group also intends to further expand its model services, explore a
pay-per-use model based on Token (a unit of measurement for information processed by models)
consumption, support medical institutions in invoking high-quality imaging analysis capabilities
on demand, lower application thresholds, promote the extension of services to primary care and
out-of-hospital health management, expand the commercialisation space for model services, raise
the baseline of primary diagnosis and treatment capabilities, and, by creating a new Zhejiang model
for “Healthy China”, enable artificial intelligence technology to more quickly benefit more people.
The collaboration will expand the commercialization potential of model services and advance the
application of artificial intelligence in disease prevention, health risk prediction and diagnosis and
treatment, which aligns with the interests of the Company and its shareholders as a whole.
About the Group
The Group is a technology company dedicated to revolutionizing medical diagnosis through
artificial intelligence. The Group has developed iMedImage ®, a foundation model that serves
as the “core general-purpose brain” for medical imaging, and has built upon it the iMedLoop™
medical imaging AI research and production acceleration platform. This platform functions like
a smart factory, combining medical imaging data with doctors’ clinical experience. It not only
assists experts in developing new models and research tools more efficiently and expanding the
upper limits of medical research and diagnostic innovation; but also transforms expert experience
into replicable and deployable models and products, so as to improve the efficiency and quality of
medical imaging diagnostics.
About Anzhen’er
Anzhen’er was jointly established and funded by Hangzhou Iron & Steel Group and Ant Group,
and is positioned as a provincial-level healthcare artificial intelligence infrastructure platform
under the guidance of the Health Commission of Zhejiang Province. Anzhen’er is an independent
third party of the Company. As the operating entity of the National Artificial Intelligence
Application Pilot Base (Medical) in Zhejiang, Anzhen’er possesses comprehensive capabilities
including national-level platform operation, large-scale application of AI agents, medical data
governance and hybrid cloud computing power. Leveraging the five major centers of the base,
including computing power assurance, data support, model research and development, verification
and evaluation, and achievement transformation, it provides full-chain support ranging from proof
of concept and R&D testing to industrialized application.

2

Forward-looking Statement
As of the date of this announcement, both parties have not entered into any specific agreement with
respect to specific cooperation projects, and any specific services and fee arrangements are subject
to further negotiation and determination. The implementation of any specific cooperation project
and its expected benefits remain subject to further negotiation between both parties, relevant
technical and commercial feasibility, and the requirements of applicable laws and regulations,
and therefore are subject to uncertainties. The cooperation as set out herein does not currently
constitute any revenue or profit forecast or commitment of the Group. The Company will make
further announcement(s) in due course in accordance with the requirements of the Listing Rules
and applicable laws and regulations.
Shareholders and potential investors of the Company are advised to exercise caution when dealing
in the securities of the Company.
By order of the Board
Hangzhou Diagens Biotechnology Co., Ltd.
Song Ning
Chairman of the Board, Executive Director and General Manager
Hangzhou, PRC, September 11, 2026

As of the date of this announcement, the Board comprises: (i) Dr. Song Ning and Mr. Weng ChihHsin (alias Robin Weng) as executive Directors; (ii) Dr. Xu Chen, Dr. Wu Lingqian and Mr. Yang
Zehao as non-executive Directors; and (iii) Mr. Cha Yang (alias Stanley Cha), Ms. Zhang Jing and
Mr. Wang Kaifeng as independent non-executive Directors.

3

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性
或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容而產生或因依賴
該等內容而引致的任何損失承擔任何責任。

Hangzhou Diagens Biotechnology Co., Ltd.
杭州德適生物科技股份有限公司
（於中華人民共和國註冊成立的股份有限公司）

（股份代號：2526）

自願性公告
與浙江省安診兒醫學人工智能科技有限公司
訂立合作框架協議
本公告由杭州德適生物科技股份有限公司（「本公司」，連同其附屬公司統稱「本集
團」）自願作出，旨在向本公司股東及潛在投資者提供最新業務進展。
本公司董事會（「董事會」）欣然宣佈，本公司與浙江省安診兒醫學人工智能科技有
限公司（「安診兒」）訂立合作框架協議，圍繞醫學影像人工智能、基層影像雲服務
及醫療數據產品開展合作，合作期限自簽訂之日起為三年。
雙方擬結合本集團iMedImage ® 的多模態醫學影像能力與安診兒獨有資源，圍繞診
前諮詢、影像初篩及報告解讀，共建「數智影像」省級能力基座，打造省級醫療大
模型應用標桿；依託安診兒的中試基地營運及醫療機構協同資源，探索「檢查在
基層、識別在雲端、審核在省級」的影像雲服務模式，共建浙江省醫療影像AI輔
助診斷雲平台；並聯合開發高質量醫療數據集、人工智能訓練語料及科研與數據
分析產品，探索醫療數據資產化新模式。
董事會認為，本次合作有助於將本集團的醫學影像基座模型及軟硬件產品能力，
與國家級中試基地的醫療資源統籌、臨床場景組織及成果轉化支撐相結合，以具
體項目推動醫療機構、科研單位與企業圍繞臨床需求協同創新，探索高質量數據
集、專病模型及創新產品的研發、驗證與應用，拓展醫療科研與診療創新的上
限。本集團亦擬進一步拓展模型服務，探索按Token（模型處理信息的計量單位）
用量付費的模式，支持醫療機構按需調用優質影像分析能力，降低應用門檻，推
動服務向基層診療及院外健康管理延伸，拓展模型服務的商業化空間，提升基層
診療能力基線，並通過打造「健康中國」的浙江新樣板使人工智能科技更快惠及
更多民眾。本次合作有助於拓展模型服務的商業化空間，推動人工智能在疾病預
防、健康風險預測及診療中的應用，符合本公司與股東的整體利益。

1

有關本集團
本集團是一家致力於以人工智能革新醫療診斷的科技企業。本集團打造了醫療影
像領域的「核心通用大腦」－iMedImage ® 基座模型，並以此建立iMedLoop™醫療
影像AI研究與生產加速平台。該平台如同一座智能工廠，將醫療影像數據與醫生
的臨床經驗相結合，既幫助專家更高效地開發新模型和研究工具，拓展醫療科研
與診療創新的上限；也將專家經驗轉化為可複製、可部署的模型和產品，提升醫
療影像診斷的效率與質量。

有關安診兒
安診兒由杭鋼集團與螞蟻集團共同出資設立，受浙江省衛生健康委員會指導，定
位為省級醫療健康人工智能基礎設施平台。安診兒為本公司的獨立第三方。作為
國家人工智能應用中試基地（醫療）浙江的營運主體，安診兒具備國家級平台營
運、智能體規模化應用、醫療數據治理及混合雲算力等綜合能力，依託基地的
算力保障、數據支撐、模型研發、驗證測評及成果轉化五大中心，提供從概念驗
證、研發測試到產業化應用的全鏈條支撐。

前瞻性陳述
截至本公告日期，雙方尚未就具體合作項目訂立具體協議，任何具體服務及計費
安排有待後續磋商確定。任何具體合作項目的落實及其預期效益，仍取決於雙方
的進一步磋商、相關技術及商業可行性以及適用法律法規的要求，故存在不確定
性。本公告所述合作目前並不構成本集團任何收入或盈利預測或承諾。本公司將
按照《上市規則》及適用法律法規的要求，於適當時候另行刊發公告。
本公司股東及潛在投資者於買賣本公司證券時務請審慎行事。
承董事會命
杭州德適生物科技股份有限公司
宋寧
董事會主席、執行董事兼總經理
中國杭州，2026年9月11日

截至本公告日期，董事會包括：(i)執行董事宋寧博士及翁資欣先生（別名Robin
Weng）；(ii)非執行董事徐晨博士、鄔玲仟博士及楊澤浩先生；及(iii)獨立非執行
董事查揚先生（別名Stanley Cha）、張競女士及王開峰先生。

2